AU2003267361A8 - Orthopoxvirus antigens and use thereof - Google Patents

Orthopoxvirus antigens and use thereof

Info

Publication number
AU2003267361A8
AU2003267361A8 AU2003267361A AU2003267361A AU2003267361A8 AU 2003267361 A8 AU2003267361 A8 AU 2003267361A8 AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A8 AU2003267361 A8 AU 2003267361A8
Authority
AU
Australia
Prior art keywords
orthopoxvirus
antigens
orthopoxvirus antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267361A
Other versions
AU2003267361A1 (en
Inventor
Caroline Staib
Ingo Drexler
Volker Erfle
Gerd Sutter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10242318A external-priority patent/DE10242318A1/en
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of AU2003267361A1 publication Critical patent/AU2003267361A1/en
Publication of AU2003267361A8 publication Critical patent/AU2003267361A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus
AU2003267361A 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof Abandoned AU2003267361A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10242318A DE10242318A1 (en) 2002-09-12 2002-09-12 Orthopox virus antigens and their use
DE10242318.0 2002-09-12
EP20020022252 EP1398380A1 (en) 2002-09-12 2002-10-02 Orthopoxvirus antigens and use thereof
EP02022252.7 2002-10-02
PCT/EP2003/010226 WO2004024756A2 (en) 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof

Publications (2)

Publication Number Publication Date
AU2003267361A1 AU2003267361A1 (en) 2004-04-30
AU2003267361A8 true AU2003267361A8 (en) 2004-04-30

Family

ID=31995061

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267361A Abandoned AU2003267361A1 (en) 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof

Country Status (2)

Country Link
AU (1) AU2003267361A1 (en)
WO (1) WO2004024756A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
WO2004067032A2 (en) * 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
ITRM20030386A1 (en) * 2003-08-05 2005-02-06 Istituto Naz Per Le Malattie Infettive Lazz METHOD AND DIAGNOSTIC TESTS BASED ON THE CITOFLUORIMETRIC ANALYSIS OF ANTIGEN-SPECIFIC T LYMPHOCYTES.
CN107735103B (en) 2015-02-25 2022-05-27 纪念斯隆-凯特琳癌症中心 Use of inactivated non-replicative modified vaccinia virus ankara (MVA) as a sole immunotherapy of solid tumors or in combination with immune checkpoint blockers
AU2016249521B2 (en) 2015-04-17 2021-08-19 Memorial Sloan Kettering Cancer Center Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN117756949A (en) * 2024-02-21 2024-03-26 中国人民解放军军事科学院军事医学研究院 Orthopoxvirus fusion antigen and application thereof

Also Published As

Publication number Publication date
AU2003267361A1 (en) 2004-04-30
WO2004024756A3 (en) 2005-01-27
WO2004024756A2 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
HK1205748A1 (en) Therapeutic epitopes and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
EP1539941A4 (en) Adzymes and uses thereof
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
MXPA03001050A (en) Rotation-retarding device and use thereof.
IL154553A0 (en) Urocortin-iii and uses thereof
AU2003296369A8 (en) Imminoamines and preparation thereof
AU2003298129A8 (en) Floor-furnace chimney and the use thereof
AU2003267361A8 (en) Orthopoxvirus antigens and use thereof
EP1589033A4 (en) Antibody and use thereof
IL166063A0 (en) Antibodies and uses thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
HK1086853A1 (en) Dispersion and use thereof
AU2003207628A8 (en) Structural and cytoskeleton-associated proteins
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
EP1367123A4 (en) Neurotonin and use thereof
GB0317376D0 (en) Immunogenic protein and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
EP1627888A4 (en) Antibody and use thereof
AU2003270876A8 (en) Anti-hla assay and methods
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase